Literature DB >> 18326820

Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells.

Javier Redondo-Muñoz1, Estefanía Ugarte-Berzal, José A García-Marco, Mercedes Hernández del Cerro, Philippe E Van den Steen, Ghislain Opdenakker, María José Terol, Angeles García-Pardo.   

Abstract

As B-cell chronic lymphocytic leukemia (B-CLL) progresses, malignant cells extravasate and infiltrate lymphoid tissues. Several molecules, including gelatinase B/MMP-9, contribute to these processes. Although mainly a secreted protease, some MMP-9 is present at the B-CLL cell surface and the function, mode of anchoring, and interactions of this MMP-9 are unknown. Here we show that anti-MMP-9 antibodies immunoprecipitated a 190-kDa CD44v isoform and alpha4beta1 integrin from B-CLL cells, but not from normal B cells. Function-blocking antibodies to alpha4beta1 or CD44, or transfection with specific siRNAs, decreased cell-associated proMMP-9 and increased the secreted form. B-CLL cells attached to and bound proMMP-9 and active MMP-9, and this was inhibited by blocking the expression or function of alpha4beta1 or CD44. The MMP-9 hemopexin domain was critical in these interactions. alpha4beta1 and 190-kDa CD44v (but not CD44H) formed a complex at the cell surface, since they both coimmunoprecipitated with anti-alpha4, anti-beta1, or anti-CD44 antibodies. Immunofluorescence analyses confirmed that alpha4beta1 and CD44v colocalized with MMP-9. Binding of proMMP-9 inhibited B-CLL cell migration, and this required MMP-9 proteolytic activity. Thus, we have identified alpha4beta1 and CD44v as a novel proMMP-9 cell surface docking complex and show that cell-associated MMP-9 may regulate B-CLL cell migration and arrest.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326820     DOI: 10.1182/blood-2007-08-109249

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  Circular trimers of gelatinase B/matrix metalloproteinase-9 constitute a distinct population of functional enzyme molecules differentially regulated by tissue inhibitor of metalloproteinases-1.

Authors:  Jennifer Vandooren; Benjamin Born; Inna Solomonov; Ewa Zajac; Radka Saldova; Michael Senske; Estefanía Ugarte-Berzal; Erik Martens; Philippe E Van den Steen; Jo Van Damme; Angeles Garcia-Pardo; Matheus Froeyen; Elena I Deryugina; James P Quigley; Søren K Moestrup; Pauline M Rudd; Irit Sagi; Ghislain Opdenakker
Journal:  Biochem J       Date:  2015-01-15       Impact factor: 3.857

Review 2.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

3.  MMP9 cleavage of the β4 integrin ectodomain leads to recurrent epithelial erosions in mice.

Authors:  Sonali Pal-Ghosh; Tomas Blanco; Gauri Tadvalkar; Ahdeah Pajoohesh-Ganji; Arpitha Parthasarathy; James D Zieske; Mary Ann Stepp
Journal:  J Cell Sci       Date:  2011-07-12       Impact factor: 5.285

4.  Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation.

Authors:  Silvia Deaglio; Fabio Malavasi
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

Review 5.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

Review 6.  Advances in understanding the leukaemia microenvironment.

Authors:  Yoko Tabe; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-01-09       Impact factor: 6.998

7.  Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia.

Authors:  Michal Reichert
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-24

8.  Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.

Authors:  Veronica C Ardi; Philippe E Van den Steen; Ghislain Opdenakker; Bernhard Schweighofer; Elena I Deryugina; James P Quigley
Journal:  J Biol Chem       Date:  2009-07-16       Impact factor: 5.157

9.  Cell Trafficking in Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Jan A Burger
Journal:  Open J Hematol       Date:  2012-02-21

10.  Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

Authors:  Suping Zhang; Christina C N Wu; Jessie-F Fecteau; Bing Cui; Liguang Chen; Ling Zhang; Rongrong Wu; Laura Rassenti; Fitzgerald Lao; Stefan Weigand; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.